Jupiter Neurosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Jupiter Neurosciences, a clinical-stage pharmaceutical company, reported significant net losses and negative cash flows for 2025, raising substantial doubt about its ability to continue as a going concern, despite launching a new consumer product line and advancing clinical trials.
NASDAQ
10-K: Jupiter Neurosciences Reports on Capital Stock, Outlines Strategy for Neuro-Inflammation Treatments
Jupiter Neurosciences' 10-K filing details its capital structure and strategic focus on developing JOTROL, a resveratrol formulation, for neuro-inflammatory conditions like Parkinson's and Alzheimer's.